Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 14/20 | 0.59 |
| ▸ | JAK2 | O60674 | 3/20 | 0.57 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL793886 | 0.90 | TYK2 (0.50) | TYK2JAK2PSMB8MEN1NPC1 | |
| SCHEMBL792969 | 0.90 | TYK2 (0.58) | TYK2JAK2PSMB8RAB9A | |
| SCHEMBL791925 | 0.90 | TYK2 (0.52) | TYK2JAK2PSMB8 | |
| SCHEMBL792395 | 0.86 | TYK2 (0.47) | TYK2JAK2PSMB8 | |
| SCHEMBL792647 | 0.86 | TYK2 (0.55) | TYK2JAK2PSMB8TRPM8 | |
| SCHEMBL792962 | 0.86 | TYK2 (0.55) | TYK2JAK2PSMB8FGFR1SRC | |
| SCHEMBL793759 | 0.84 | TYK2 (0.47) | TYK2JAK2SRCAPP | |
| SCHEMBL793073 | 0.84 | TYK2 (0.50) | TYK2JAK2PSMB8NPC1RAB9A | |
| SCHEMBL792917 | 0.84 | TYK2 (0.48) | TYK2JAK2MEN1KMT2A | |
| SCHEMBL793080 | 0.83 | TYK2 (0.43) | TYK2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171408-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-06-19 | — | — | US | claimed |
| US-20120202788-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | claimed |
| US-20140171408-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8697708-B2 | Azabenzothiazole compounds, compositions and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-15 | — | — | US | disclosed |
| EP-2616072-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-20120202788-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| WO-2012035039-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171408-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F12, CHRM1, NPY1R | TYK2 229/4885JAK2 544/4885PSMB8 2354/4885 |
| US-20120202788-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F12, CHRM1, NPY1R | TYK2 229/4885JAK2 544/4885PSMB8 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.